PMID- 10492041
OWN - NLM
STAT- MEDLINE
DCOM- 19990922
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 30
IP  - 9
DP  - 1999 Sep
TI  - Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's 
      disease using a novel monoclonal marker, YTH-2H12.
PG  - 1065-70
AB  - Inhibitors of apoptosis may regulate tissue differentiation and promote cell 
      survival in neoplasia. A new apoptosis inhibitor of the bcl-2 gene family, 
      bcl-X(L), was recently found in some types human neoplasia but not in normal 
      tissue. We investigated bcl-X(L) expression in 419 cases of normal and neoplastic 
      lymphoid lesions using immunohistochemistry with the monoclonal antibody bcl-X(L) 
      (YTH-2H12). Ninety-four percent (141/150) of classic Hodgkin's disease (HD) were 
      positive for bcl-X(L) with strong intensity in most Reed-Sternberg (RS) cells. 
      Forty-eight percent (38/80) of nodular lymphocyte predominance (LPHD) were 
      positive. In the non-Hodgkin's lymphomas (NHL), bcl-X(L) was expressed in a low 
      percentage of cases (< 20%), with the exception of follicle center lymphoma, 
      grade III/III (78%). All reactive hyperplastic lesions were negative for 
      bcl-X(L). RS cells, which expressed bcl-X(L), were not labeled by terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). We found RS 
      cells expressing bcl-X(L) were absent of DNA fragmentation (apoptosis). Our data 
      provide evidence that bcl-X(L) is abnormally expressed in the RS cells of HD and 
      some types of NHL raising speculation that inhibition of apoptosis may be 
      important in the pathogenesis of lymphoma, specifically HD. In addition, the 
      previously reported correlation between bcl-X(L) and Epstein-Barr virus 
      expression in HD was not supported by this study.
FAU - Chu, W S
AU  - Chu WS
AD  - Department of Hematopathology, Armed Forces Institute of Pathology, Washington, 
      DC 20306-6000, USA.
FAU - Aguilera, N S
AU  - Aguilera NS
FAU - Wei, M Q
AU  - Wei MQ
FAU - Abbondanzo, S L
AU  - Abbondanzo SL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (BCL2L1 protein, human)
RN  - 0 (Bcl2l1 protein, mouse)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (EBV-associated membrane antigen, Epstein-Barr virus)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (bcl-X Protein)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*immunology
MH  - *Apoptosis
MH  - Biomarkers, Tumor/*biosynthesis
MH  - Burkitt Lymphoma/metabolism/pathology
MH  - Herpesvirus 4, Human/isolation & purification
MH  - Hodgkin Disease/*metabolism/pathology
MH  - Humans
MH  - Immunoblotting
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Infectious Mononucleosis/metabolism
MH  - Lymphoma, Non-Hodgkin/metabolism/pathology
MH  - Lymphoma, T-Cell/metabolism/pathology
MH  - Mice
MH  - Proto-Oncogene Proteins c-bcl-2/*biosynthesis/immunology
MH  - Reed-Sternberg Cells/*metabolism/pathology
MH  - Tumor Cells, Cultured
MH  - Viral Matrix Proteins/metabolism
MH  - bcl-X Protein
EDAT- 1999/09/24 00:00
MHDA- 1999/09/24 00:01
CRDT- 1999/09/24 00:00
PHST- 1999/09/24 00:00 [pubmed]
PHST- 1999/09/24 00:01 [medline]
PHST- 1999/09/24 00:00 [entrez]
AID - S0046-8177(99)90224-1 [pii]
AID - 10.1016/s0046-8177(99)90224-1 [doi]
PST - ppublish
SO  - Hum Pathol. 1999 Sep;30(9):1065-70. doi: 10.1016/s0046-8177(99)90224-1.